Cargando…
Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin
The aim of this study was to characterize the treatment response and tolerability of sofosbuvir plus ribavirin therapies in Japanese patients infected with hepatitis C virus (HCV) genotype (GT)-2. This retrospective study analyzed 114 Japanese HCV GT-2 patients treated for 12 weeks with 400 mg of so...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485477/ https://www.ncbi.nlm.nih.gov/pubmed/28486403 http://dx.doi.org/10.3390/biology6020030 |
_version_ | 1783246070956949504 |
---|---|
author | Kanda, Tatsuo Nakamura, Masato Yasui, Shin Haga, Yuki Tawada, Akinobu Suzuki, Eiichiro Ooka, Yoshihiko Takahashi, Koji Sasaki, Reina Wu, Shuang Nakamoto, Shingo Arai, Makoto Imazeki, Fumio Yokosuka, Osamu |
author_facet | Kanda, Tatsuo Nakamura, Masato Yasui, Shin Haga, Yuki Tawada, Akinobu Suzuki, Eiichiro Ooka, Yoshihiko Takahashi, Koji Sasaki, Reina Wu, Shuang Nakamoto, Shingo Arai, Makoto Imazeki, Fumio Yokosuka, Osamu |
author_sort | Kanda, Tatsuo |
collection | PubMed |
description | The aim of this study was to characterize the treatment response and tolerability of sofosbuvir plus ribavirin therapies in Japanese patients infected with hepatitis C virus (HCV) genotype (GT)-2. This retrospective study analyzed 114 Japanese HCV GT-2 patients treated for 12 weeks with 400 mg of sofosbuvir plus weight-based ribavirin daily. This treatment led to higher sustained virologic response at 12-weeks post-treatment (SVR12) rates in both treatment-naïve and treatment-experienced patients. The efficacy of this treatment in compensated cirrhotics was the same as that in patients with chronic hepatitis. HCV GT-2a infection and lower estimated glomerular filtration rates (eGFR) tended to be associated with SVR12. Of 114 patients, 113 completed the combination of sofosbuvir plus ribavirin for 12 weeks. Seven patients without SVR12 did not have HCV NS5B-S282 mutations. The overall SVR12 rate was 90.4% (103 of 114). More effective therapeutic options with less adverse events are desired to achieve higher SVR rates in HCV GT-2 Japanese patients. |
format | Online Article Text |
id | pubmed-5485477 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-54854772017-06-29 Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin Kanda, Tatsuo Nakamura, Masato Yasui, Shin Haga, Yuki Tawada, Akinobu Suzuki, Eiichiro Ooka, Yoshihiko Takahashi, Koji Sasaki, Reina Wu, Shuang Nakamoto, Shingo Arai, Makoto Imazeki, Fumio Yokosuka, Osamu Biology (Basel) Article The aim of this study was to characterize the treatment response and tolerability of sofosbuvir plus ribavirin therapies in Japanese patients infected with hepatitis C virus (HCV) genotype (GT)-2. This retrospective study analyzed 114 Japanese HCV GT-2 patients treated for 12 weeks with 400 mg of sofosbuvir plus weight-based ribavirin daily. This treatment led to higher sustained virologic response at 12-weeks post-treatment (SVR12) rates in both treatment-naïve and treatment-experienced patients. The efficacy of this treatment in compensated cirrhotics was the same as that in patients with chronic hepatitis. HCV GT-2a infection and lower estimated glomerular filtration rates (eGFR) tended to be associated with SVR12. Of 114 patients, 113 completed the combination of sofosbuvir plus ribavirin for 12 weeks. Seven patients without SVR12 did not have HCV NS5B-S282 mutations. The overall SVR12 rate was 90.4% (103 of 114). More effective therapeutic options with less adverse events are desired to achieve higher SVR rates in HCV GT-2 Japanese patients. MDPI 2017-05-09 /pmc/articles/PMC5485477/ /pubmed/28486403 http://dx.doi.org/10.3390/biology6020030 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kanda, Tatsuo Nakamura, Masato Yasui, Shin Haga, Yuki Tawada, Akinobu Suzuki, Eiichiro Ooka, Yoshihiko Takahashi, Koji Sasaki, Reina Wu, Shuang Nakamoto, Shingo Arai, Makoto Imazeki, Fumio Yokosuka, Osamu Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin |
title | Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin |
title_full | Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin |
title_fullStr | Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin |
title_full_unstemmed | Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin |
title_short | Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin |
title_sort | treatment of real-world hcv genotype 2-infected japanese patients with sofosbuvir plus ribavirin |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485477/ https://www.ncbi.nlm.nih.gov/pubmed/28486403 http://dx.doi.org/10.3390/biology6020030 |
work_keys_str_mv | AT kandatatsuo treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT nakamuramasato treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT yasuishin treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT hagayuki treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT tawadaakinobu treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT suzukieiichiro treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT ookayoshihiko treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT takahashikoji treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT sasakireina treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT wushuang treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT nakamotoshingo treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT araimakoto treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT imazekifumio treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin AT yokosukaosamu treatmentofrealworldhcvgenotype2infectedjapanesepatientswithsofosbuvirplusribavirin |